Skip to main content
. Author manuscript; available in PMC: 2018 Dec 17.
Published in final edited form as: Clin Cancer Res. 2017 Dec 29;24(6):1415–1425. doi: 10.1158/1078-0432.CCR-17-2283

Fig 1. In vivo model of hepatic micrometastatic pancreatic ductal adenocarcinoma (PDAC).

Fig 1.

A) Schematic of PDAC cell line establishment and the in vivo model. B) Gross necropsy specimens and H&E staining of livers harvested from mice at 1 day, 22 days, and 45 days after splenic injection of patient-derived PDAC (T608) cells. C) Hepatic tumor burden is tracked with serial in vivo bioluminescence imagining. A representative mouse at different time points following splenic injection of PDAC (T608) cells (top) and a growth curve of hepatic tumor burden relative to 48 hours post-splenic injection (n = 11). Data are expressed as median ± interquartile range. The dotted line represents a relative hepatic tumor burden of 2.0, defined as disease progression. D) Kaplan-Meier curves of time-to-progression for five patient-derived PDAC cell lines (T366: n = 38, T395: n = 21, T449: n = 14, T608: n = 101, T738: n = 15).